Appleton Partners’s Altimmune ALT Stock Holding History

Appleton Partners’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-35	Closed	-$30K	–	210
2016 Q3	$30K	Buy	+35	New	+$27.5K	0.01%	211

Other funds holding ALT

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PGCM

Prescott Group Capital Management Tulsa, Oklahoma $1B AUM 51.95% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NRCM

Northern Right Capital Management Darien, Connecticut $281M AUM 56.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Appleton Partners's ALT Position: Q4 2016 in Review

Appleton Partners sold out of Altimmune (ALT) in Q4 2016, closing a stake of 35 shares — an estimated $30K sold.

Appleton Partners first reported a position in ALT in Q3 2016 and held it in 1 quarter. The position peaked at $30K in Q3 2016. 88 funds tracked by Wall St. Rank hold ALT as of Q4 2016.

Appleton Partners reported no remaining Altimmune position as of Q4 2016 after selling out during the quarter.
Appleton Partners sold 35 Altimmune shares in Q4 2016, an estimated $30K.
Appleton Partners first reported a position in Altimmune in Q3 2016 and held it in 1 quarter.
Appleton Partners's Altimmune position peaked at $30K in Q3 2016.
88 funds tracked by Wall St. Rank held Altimmune as of Q4 2016.

Based on Appleton Partners's 13F filing for Q4 2016, filed 13 Feb 2017.